

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/12, C12Q 1/68, C07K 14/47	A1	(11) International Publication Number: <b>WO 99/27090</b> (43) International Publication Date: 3 June 1999 (03.06.99)
<p>(21) International Application Number: PCT/GB98/03445</p> <p>(22) International Filing Date: 20 November 1998 (20.11.98)</p> <p>(30) Priority Data: 60/066,241 20 November 1997 (20.11.97) US</p> <p>(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US). SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BERTRAM, Timothy [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). BROWNE, Michael, J. [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). BUGELSKI, Peter [US/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB). ENGLAND, Paul [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MITCHELL, Ian [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6</p>	<p>9AR (GB). RUT, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MORGAN, Gwyn [GB/GB]; SmithKline Beecham Pharmaceuticals, The Frythe, Welwyn, Hertfordshire AL6 9AR (GB).</p> <p>(74) Agent: GIDDINGS, Peter, John; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p>	
(54) Title: METHODS FOR IDENTIFYING THE TOXIC/PATHOLOGIC EFFECT OF ENVIRONMENTAL STIMULI ON GENE TRANSCRIPTION		
<p>(57) Abstract</p> <p>Methods are disclosed for assessing the toxic or pathologic effects of a selected environmental stimulus or reagent on a mammalian cell by determining on a DNA grid a "fingerprint" hybridization pattern. The fingerprint pattern is characteristic of chemically or structurally diverse stimuli or reagents, which have a common adverse effect on gene transcription. A test compound is screened for a similar toxic effect by comparing its hybridization pattern on a similar grid to the fingerprint.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## METHODS FOR IDENTIFYING THE TOXIC/PATHOLOGIC EFFECT OF ENVIRONMENTAL STIMULI ON GENE TRANSCRIPTION

5           The present invention relates to the use of arrays or grids of mammalian gene sequence fragments from genomic (or cDNA) libraries for the screening of environmental factors, such as pharmaceutical compounds, physical factors, infectious agents, etc, for a toxic or pathologic effect upon gene transcription.

          Mammalian cells frequently respond to exogenous stimuli of many types by  
10   altering the rate of transcription. For example, exposure of mammalian cells to environmental factors such as ultraviolet light, pharmaceutical compounds and many others can increase or decrease the quantity of messenger RNA produced by the cells. These changes in transcriptional regulation can result in toxic or pathological responses by the mammal. For example, where the external stimuli is prolonged  
15   exposure to UV rays, the toxic response of the mammal can be sunburn. Where the external stimuli is a compound known to be hepatotoxic, the response is liver damage. Where the external stimuli is a carcinogen, the toxic response is uncontrolled growth of cells.

          The development of new pharmaceutical compositions and/or treatment  
20   regimens directed towards the treatment or prophylaxis of a variety of diseases, infectious or otherwise, relies quite heavily on the ability to screen candidate reagents for possible toxic or pathologic response. In normal drug development a novel chemical compound, novel biological composition, and the like is run through a battery of assays *in vitro* and in laboratory animals to ascertain its safety (i.e., lack  
25   of toxicity) and effectiveness.

          The costs associated with the development of new pharmaceutical reagents are ever increasing, particularly when new compositions enter clinical trials. It is not unknown for promising pharmaceutical candidates to pass the appropriate laboratory tests and enter the expensive stage of animal and human clinical trials; only to  
30   present toxic or pathologic effects in the *in vivo* setting for the targeted mammalian patient, normally humans. The elimination of previously promising drug candidates at such a late stage in product development is a major factor in the high costs of new effective drugs which ultimately do pass the final clinical trials. Such late elimination of toxic compounds also results in unnecessary human suffering and  
35   wasted effort.

          Methods have been described for obtaining information about gene expression and identity using so called "high density DNA arrays" or grids. See,

e.g., M. Chee et al, Science, 274:610-614 (1996) and other references cited therein. Such gridding assays have been employed to identify certain novel gene sequences, referred to as Expressed Sequence Tags (EST) [Adams et al., Science, 252:1651-1656 (1991)]. A variety of techniques have also been described for identifying  
5 particular gene sequences on the basis of their gene products. For example, see International Patent Application No. WO91/07087, published May 30, 1991. In addition, methods have been described for the amplification of desired sequences. For example, see International Patent Application No. WO91/17271, published November 14, 1991.

10 Accordingly, there exists a need for more efficient methods for screening novel pharmaceutical reagents, as well as other environmental stimuli or factors, to identify any toxic/pathogenic effect on gene transcription for both new drug development and new therapeutic regimens.

15 In one aspect, the invention provides a method of assessing the genetic effect of a selected environmental factor on a mammalian subject, said method comprising the steps of:

- (a) providing a plurality of identical grids, each grid comprising a surface on which is immobilized at predefined regions on said surface a plurality of unique defined gene sequence fragments, said oligonucleotide sequences comprising genes  
20 or fragments of genes obtained from a healthy member of said mammalian species;
- (b) exposing mammalian cells, tissue or organ to an environmental factor for a sufficient time to affect transcription of messenger RNA in said cells;
- (c) extracting and isolating mRNA from said exposed cells, tissue or organ of step (b);
- 25 (d) extracting and isolating control mRNA from mammalian cells, tissue or organ not exposed to said factor;
- (e) labelling the mRNA from steps (c) and (d);
- (f) hybridizing the labeled mRNA from the exposed cells, tissue or organ to a first identical grid to produce a first hybridization pattern detectable by an  
30 increased quantity of fluorescence in contrast to the remainder of the grid;
- (g) hybridizing the labeled control mRNA to a second identical grid to produce a second, control hybridization pattern; and
- (h) comparing the first and second hybridization patterns to identify any  
35 change in said first pattern from the control pattern, indicative of an effect on transcriptional regulation of said mammalian cells, tissue or organ exposed to said factor.

The method of the invention thus employs the following steps. A plurality of identical DNA grids is prepared. At predefined regions on the grid surface, a plurality of defined amplified gene sequences (or oligonucleotide sequences) is immobilized. These gene sequences preferably are known or unknown genes, or fragments of genes, obtained from the cells (or a library of cells) of a healthy member of the mammalian species. Messenger RNA is isolated and extracted from mammalian cells which are not exposed to a selected environmental stimulus, thus forming the "control" RNA. The "test mRNA" is extracted from mammalian cells which have been exposed for a sufficient time to affect gene transcription to the selected stimulus. The control and test mRNA are randomly labeled, and each mRNA preparation is applied to an identical grid. The respective hybridization patterns are compared to identify any change in the test pattern from the control pattern, indicative of an effect on transcriptional regulation of the mammalian cells exposed to the stimulus. The determination of stimuli having a toxic or pathologic effect is useful, e.g., in the screening and development of new pharmaceutical agents and therapies.

The arrays or grids of mammalian gene sequence fragments from genomic (or cDNA) libraries used in the method of the invention may be high density DNA arrays or grids.

In another aspect, the method described above is performed for a "class" of stimuli, e.g., chemical or pharmaceutical compounds, which are to generate a common toxic or pathologic effect upon exposure to mammalian cells, e.g., hepatotoxicity. The method generates a "fingerprint" hybridization pattern for e.g., hepatotoxic, stimuli. Thus, test candidate drugs compositions may be screened for the likelihood of causing hepatotoxicity in mammalian cells by comparing the test hybridization pattern to the fingerprint at an early stage in drug development. Similarity between the fingerprint and the test pattern permit early elimination of the candidate drug from consideration, thus permitting only non-hepatotoxic compounds to proceed to drug development.

In still another aspect, the methods of the present invention may be performed to identify those genes which are the most responsive to a particular toxic effect of an external stimuli.

In still further aspects, the invention provides methods of identifying possible toxic or pathological effects of a variety of disparate physical stimuli, as well as chemical and pharmaceutical stimuli.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should

be understood, however, that the following description, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

The present invention meets the needs of the art by providing a method of assessing the effect of any environmental factor or stimulus on gene expression in a mammalian subject by using DNA gridding techniques. Such techniques, employed as described below, permit the identification of genes which display a response to a test compound, permit the identification of a hybridization pattern characteristic of known physiologic effect in response to a test compound and permit the "fingerprinting" of certain selected toxic effects. The fingerprints are useful in screening new compounds or drug candidates for potential toxicity and in screening for the effect on gene transcription of other environmental stimuli. The information generated thereby can be used in the pharmaceutical industry to identify new drugs, in occupational safety evaluations of the workplace environment, and in many other industries and settings where it may be necessary to take measures to correct environmental stimuli which cause adverse effects in humans, and other mammals.

Several words and phrases used throughout this specification are defined as follows:

As used herein, the term "gene" refers to the genomic nucleotide sequence from which a cDNA sequence is derived. The term gene classically refers to the genomic sequence, which upon processing, can produce different RNAs.

By "gene product" it is meant any polypeptide sequence, peptide or protein, encoded by a gene. The term "genomic library" is meant to include, but is not limited to, plasmid libraries, PCR products from genomic libraries, cDNA libraries and known sequences. Methods for the construction of such libraries are well known by those skilled in the art. A genomic library may be adjusted to minimize the number of complete genes present in a single genomic insert to approximately one gene. Techniques for this adjustment are well known to the skilled artisan.

"Isolated" means altered "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal in its natural state is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated,"



as the term is employed herein. For example, with respect to polynucleotides, the term isolated means that it is separated from the chromosome and cell in which it naturally occurs.

5 "Pathogenic effect" or "pathologic effect", as used herein, refers to a change in gene expression which may cause a disease or disorder. The change is due to exposure of a mammal or mammalian cell to some environmental stimulus, as detailed below.

As used herein, the term "solid support" refers to any substrate which is useful for the immobilization of a plurality of defined materials derived from a genomic library by any available method to enable detectable hybridization of the  
10 immobilized polynucleotide sequences with other polynucleotides in the sample. Among a number of available solid supports, one desirable example is the support described in International Patent Application No. WO91/07087, published May 30, 1991. Examples of other useful supports include, but are not limited to,  
15 nitrocellulose, nylon, glass, silica and Pall BIODYNE C membrane. It is also anticipated that improvements yet to be made to conventional solid supports may also be employed in this invention.

The term "grid" means any generally two-dimensional structure on a solid support to which the defined materials of a genomic library are attached or  
20 immobilized. Preferably according to this invention, three types of grids are useful. One grid useful in this invention contains as its defined oligonucleotide materials, unique nucleic acid sequences [or "tags"; or expressed sequence tags ("EST")] from all human genes identified. A second useful grid contains unique nucleic acid ESTs from genes cloned from a tissue or a cell line. Still a third type of grid useful in the  
25 present invention contains unique nucleic acid tags from genes classified as particularly relevant to identification of a selected environmental toxicity. Grids are desirably constructed from animal species used in the preclinical assessment of compound safety.

As used herein, the term "predefined region" refers to a localized area on a  
30 surface of a solid support on which is immobilized one or multiple copies of a particular amplified gene region or sequence and which enables hybridization of that clone at the position, if hybridization of that clone to a sample polynucleotide occurs.

By "immobilized," it is meant to refer to the attachment of the genes to the  
35 solid support. Means of immobilization are known and conventional to those of skill in the art, and may depend on the type of support being used.

The terms "environmental factor" or "environmental stimuli" are used herein to describe a wide variety of physical, chemical or biological factors which cause changes in gene transcription in a mammalian cell when the mammal itself, or a culture of such mammalian cells, is exposed to that factor. For example, physical environmental stimuli can include, without limitation, the diet of the mammal, an increase or decrease in temperature; an increase or decrease in exposure to ionizing or ultraviolet radiation, and the like. A biological/chemical stimuli can include, without limitation, administering a transgene to the mammal, or eliminating a gene from the mammal; administering an exogenous synthetic compound or exogenous agent or an endogenous compound, agent or analog thereof to the mammal.

As an example, an exogenous synthetic compound can be a pharmaceutical compound, a toxic compound, a protein, a peptide, a chemical composition, among other. An exogenous agent can include natural pathogens, such as microbial agents, which can alter gene transcription. Examples of pathogens include bacteria, viruses, and lower eukaryotic cells such as fungi, yeast, molds and simple multicellular organisms, which are capable of infecting a mammal and replicating its nucleic acid sequences in the cells or tissue of that mammal. Such a pathogen is generally associated with a disease condition in the infected mammal.

An endogenous compound is a compound which occurs naturally in the body. Examples include hormones, enzymes, receptors, ligands, and the like. An analogue is an endogenous compound which is preferably produced by recombinant techniques and which differs from said naturally occurring endogenous compound in some way.

By "transcriptional effect" is meant an increase or decrease in rate of transcription in the mammalian cells exposed to the stimuli.

A "fingerprint" as used herein is defined as a characteristic hybridization pattern on a grid indicating a common toxicological response, i.e., similar increases in gene transcription that result in similar tissue damage. For example, using the methods described herein, one may generate a "hepatotoxic" fingerprint, which can be used to identify compounds which are likely to have a toxic effect on the liver, and so on.

By "label" as used herein is meant any conventional molecule which can be readily attached to mRNA and which can produce a detectable signal, the intensity of which indicates the relative amount of hybridization of the mRNA to the DNA fragment (oligonucleotide) on the grid. Preferred labels are fluorescent molecules or radioactive molecules. A variety of well-known labels can be used.

## Method of the Invention:

### A. The Grids

According to the present invention, a method is provided which enables the association of selected environmental stimuli with changes in gene transcription.

- 5 One of the specific applications of this technology is the understanding and prediction of toxic reactions to environmental manipulations and modifications, such as those stimuli listed above. Another application is in pre-clinical and clinical drug development, where the method of this invention enables the screening of compounds having a similar toxic effect on gene transcription by comparison to the effect of another stimulus.

- 10 In the practice of this method, a plurality of identical grids is prepared, so that each grid carries on its solid surface a plurality of defined unique gene (oligonucleotide) sequences immobilized at predefined regions on the surface. The gene sequences immobilized on the grids are as defined above, i.e., as unique nucleic acid tags from all human or other mammalian genes, or from only a selected tissue, e.g., reticulocytes, or the liver, or a selected cell line, or from genes known to be relevant to environmental toxicity, e.g., the lung, kidney, heart, blood cells, etc. These genes or fragments of genes immobilized on the grids may be obtained from an oligonucleotide library of a healthy member of the mammalian species, e.g., a healthy human. Other mammals of interest include, without limitation, a non-human primate, a rodent, and a canine.

- 25 For the purposes of this invention, it is not necessary that the grids reflect a single target organ, although such a specific target grid can be used. It is anticipated that the response of the mammalian cell to various environmental stimuli that effect gene transcription is likely to be stereotypic of genes in other cells. Thus, the grid can be prepared from red or white blood cells, reticulocytes, or undifferentiated cells, even where the particular toxicological effect is damage to the liver or some other particular tissue. Alternatively, such a grid can be prepared from hepatocytes only, or from cells from the effected organ or tissue only. All grids are anticipated to reflect the same hybridization pattern upon exposure to a reagent or stimulus that is known as hepatotoxic. The same is true regardless of the type of toxicological damage, e.g., cardiac damage, kidney damage, hematopoietic cell damage, etc.

- 30 The gene fragments immobilized on the grid may be obtained from a random cDNA library of the target mammal using known techniques. Alternatively, a cDNA library of genes from a selected organ or tissue may be prepared as the source of the sequences immobilized on the grid. The RNA is isolated and reverse transcribed to cDNA using standard procedures for molecular biology such as those

disclosed by Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed; Cold Spring Harbor Laboratory Press, Cold Spring Harbor Lab Press, Cold Spring Harbor, NY 1989. The cDNA library is then constructed in accordance with procedures described by Fleischmann et al. Science, 1995, 269:496-

5 512. For the purposes of the present invention, a cDNA library can comprise a plasmid library, PCR products from a cDNA library, or known sequences.

A plurality of genes or gene fragments, whether known or random and unknown, from the selected library are gridded onto a surface of a solid support at predefined locations or regions, preferably at 6X coverage. By "plurality of  
10 materials derived from the genomic library" it is meant to include, but is not limited to, individual clones spotted onto and grown on a surface of the solid support at predefined locations or regions; or plasmid clones isolated from said library, PCR products derived from the plasmid clones, or oligonucleotides derived from sequencing of the plasmid clones, which are immobilized to the surface of the solid  
15 support at predefined locations or regions. As selection of genes involved in e.g., carcinogenicity, apoptosis, inflammation, metabolism of compounds etc, may be used.

The grids used in the invention may contain, e.g., up to 5,000 genes or gene fragments. The grids preferably contain up to 1,500 genes or gene fragments, e.g.,  
20 100 to 1,500 genes or gene fragments, more preferably about 1,000 genes or gene fragments.

Numerous conventional methods are employed for immobilizing these gene sequences (oligonucleotides) to surfaces of a variety of solid supports. See, e.g., Affinity Techniques, Enzyme Purification: Part P, Methods in Enzymology, Vol.  
25 34, ed. W.B. Jakoby, M. Wilcheck, Acad. Press, NY (1971); Immobilized Biochemicals and Affinity Chromatography, Advances in Experimental Medicine and Biology, Vol. 42, ed. R. Dunlap, Plenum Press, NY (1974); U.S. Patent 4,762,881; U.S. Patent No. 4,542,102; European Patent Publication No. 391,608 (October 10, 1990); or U.S. Patent No. 4,992,127 (November 21, 1989).

30 One desirable method for attaching these materials to a solid support is described in International Application No. PCT/US90/06607 (published May 30, 1991). Briefly, this method involves forming predefined regions on a surface of a solid support, where the predefined regions are capable of immobilizing the materials. The method makes use of binding substrates attached to the surface  
35 which enable selective activation of the predefined regions. Upon activation, these binding substances become capable of binding and immobilizing the materials derived from the genomic library.

Any of the known solid substrates suitable for binding nucleotide sequences at predefined regions on the surface thereof for hybridization and methods for attaching nucleotide sequences thereto may be employed by one of skill in the art according to the invention.

- 5           As described above the genes or gene fragments may be of known or unknown function. In a fingerprinting method it is not necessary to know the function of every gene since the method may not be looking at specific pathways of toxicity but at distinct patterns of gene expression in response to environmental factors.

10    B.       Obtaining the mRNA for hybridization to the grids

- The selected mammalian cells, tissues or organs to be examined for transcription changes are subjected to the environmental stimulus for a sufficient time to affect transcription of messenger RNA in the cells. This "exposing" step can occur by treating or exposing a living healthy animal or human to the stimulus. For  
15    example, the selected mammal may be administered a reagent, such as an exogenous or endogenous compounds as described above. Alternatively, the mammal may be exposed to a physical stimulus, e.g., UV radiation.

- Alternatively, a mammalian cell culture or tissue culture, or viable organ, e.g., liver, heart, etc., may be exposed to the stimulus *in vitro*. A control mRNA  
20    source is an untreated animal, tissue, organ or cell culture.

- The exposure to the environmental stimulus, which may be stimuli known to cause a specific physical effect, e.g., hepatocyte damage, cancer, etc., occurs for a time sufficient to result in the alteration from the normal of the transcription level of the cells so exposed. The sufficient time will depend upon the particular stimulus  
25    being studied and, in fact, determination of a sufficient stimulus time is well within the skill of the art.

- Where the mRNA source is a cell culture, the culture is then incubated under a selected set of defined *in vitro* or *in vivo* conditions to produce a test culture. In addition, non-exposed cells are also cultured under the same set of defined  
30    conditions to produce a control culture. By "defined conditions" it is meant, but is not limited to, standard *in vitro* culture conditions recognized as normal (i.e., non-pathogenic) for a selected mammalian cell, as well as *in vitro* conditions which reflect or mimic *in vivo* pathogenic settings (conditions) such as heat shock, auxotrophic, osmotic shock, antibiotic or drug selection/addition varied carbon  
35    sources, and aerobic or anaerobic conditions, and *in vivo*, pathogenic conditions. Preferably, such conditions are predetermined to allow maximum growth of the non-exposed cells.

The cells are then harvested from the animal, organ, tissue or cell culture by conventional means. Harvesting can be performed during various growth stages of the cells to ascertain the essentiality of a particular gene during different stages of growth. For example, harvesting can be performed during early logarithmic growth, late logarithmic growth, stationary phase growth or late stationary growth. RNA (or DNA) is then extracted and isolated from the harvested non-exposed cells of the control culture, and RNA is extracted and isolated from the cells exposed to the stimulus of the test culture using standard methodologies well known to those skilled in the art.

mRNA extracted from the cells of the control culture and from the cells of the test culture are then used to generate labeled probes. When mRNA from the control and test cells is used to generate the probes, isolated mRNA is labeled according to standard methods using random primers, preferably hexamers, and reverse transcriptase. Such methods are routinely performed by those skilled in the art. All mRNA from the "control" or the "exposed" source is randomly labeled by conventional means, such as nick translation, multiprime labelling or other commonly used enzymatic labeling methodology. Known conventional methods for labelling the mRNA sequences may be used and make hybridization of the immobilized materials detectable. For example, fluorescence, radioactivity, photoactivation, biotinylation, energy transfer, solid state circuitry, and the like may be used in this invention.

C. Hybridization to the grids

These labeled mRNAs are then used as hybridization probes against the identical high density grids. Labeled probes prepared from mRNA extracted from the test culture are hybridized to one grid to produce a "test" hybridization pattern. Labeled probes from the mRNA extracted from the cells of the control culture are hybridized to a second identical grid, resulting in a "control" hybridization pattern.

The generated test hybridization patterns and control hybridization patterns are then compared. In the control pattern, the mRNA binds to certain genes or gene fragments in the grid in proportion to the expression of the mRNA of such genes in a normal cell. The pattern is detectable by an increased quantity of detectable signal, e.g., fluorescence, at locations on the grid of those genes which are normally expressed in greater quantities than others in the remainder of the grid.

In the test grid, genes for which transcription is enhanced by the stimulus will be bound by a greater amount of labeled mRNA, and genes for which transcription is reduced by the stimulus will be bound by a lesser amount of labeled mRNA, thus altering the hybridization pattern from that of the control. Comparison

of the test and control patterns reveals the effect of the test compound on transcription of certain genes located at the predefined locations on other grid.

#### D. The Fingerprints

Thus, where the test compound or stimulus is a stimulus known to cause a physiological effect, for example, a toxic reaction of a subject resulting in damage to a major organ, e.g., liver, kidney, heart, blood cells, the method of this invention may be performed to provide a hybridization pattern which correlates with that damage. Most desirably, for preclinical drug screening according to this invention, any collection of known and structurally distinct toxicants which have the same physiological effects, e.g., hepatotoxicity, can be employed in this method to generate a characteristic "fingerprint" hybridization pattern for hepatotoxic stimuli.

Where it is desired to produce a common hybridization pattern such known toxicants, a set of grids are calibrated with a repertoire of the structurally diverse toxicants that produce the same pathological/toxicological reaction; e.g. hepatotoxicity or nephrotoxicity. In other words, labeled RNA from a mammalian cell source exposed to the known toxicants are hybridized to identical grids to produce a common toxicant hybridization pattern. If the variety of known toxicants produce a characteristic common hybridization pattern, the common toxicological responses are likely to be the result of similar increases in transcription of selected genes, resulting in similar tissue damage. This toxicological fingerprint pattern may be used along with the "control" pattern for comparison with the pattern of a test compound/stimulus of unknown function or result. Thus the common fingerprint for, e.g., hepatotoxicity, is used to screen a stimulus of unknown function or effect to determine if that stimulus is likely to produce hepatotoxicity in the mammal.

Similarity in the "test" pattern to the hepatotoxic fingerprint enables the putative identification of the test compound as a hepatotoxic compound. Thus, if the test compound was a drug candidate, it can be eliminated from consideration at the earliest stages of drug development on the basis of its effects on gene transcription as measured on the grids. Similarly the method permits the test compound or stimulus, if an environmental factor present in e.g., the workplace, such as radiation, etc., to be identified as a potential health hazard, and corrected.

According to this method, therefore, a battery of fingerprint hybridization patterns may be prepared for all known toxicants. Any new drug candidate or other environmental stimulus may be screened by the above method for probable toxicological effects by comparison to standard fingerprints for other known stimuli causing liver damage, kidney damage, damage to the hematopoietic systems, etc.

Such a screening method will enable quick and early evaluation of environmental stimuli, particularly new drug candidates.

Fingerprint hybridization patterns may be stored in a database and pattern matching performed by datamining.

5 E. Preclinical Embodiments of the Method

In a particularly desirably embodiment of the method of this invention, *in vitro* effects of pharmacologically relevant concentrations of compounds on gene expression in blood cells are examined using the methods of this invention. A gene expression fingerprint is developed through this methodology by exposing the  
10 nucleated blood cells, e.g., reticulocytes, white cells, to a variety of toxicants as described above. The resulting fingerprint is used subsequently to predict whether a novel compound is likely to also produce a similar pathological reaction. The information assists decisions about which compounds to take forward to clinical development, and enhances safety in the clinic through accurate and early prediction  
15 of toxicity.

An alternative embodiment of the method of this invention is to analyze the *in vitro* effects of pharmacologically relevant concentrations of compounds on gene expression in blood cells.

20 The Genes and Proteins Identified by the Method:

In still another embodiment, the method described above, and/or the fingerprints generated for certain selected toxicities may be useful in identifying novel genes that may have a significant impact on the compound's toxicity. Application of the compositions and methods of this invention as above described  
25 also provides other compositions, such as any isolated gene sequence which is unusually reactive to the toxic result of one or more known toxicants.

For example, in a desirable embodiment, the methods of this invention is useful in a clinical setting. Gene expression grids may aid in the identification of the mechanism underlying the occurrence of pathological reactions and toxicity in a  
30 minority of patients during human trials. Using human grids, gene expression in cells derived from patients/volunteers known to have experienced the adverse event in question during a clinical trial can be compared to gene expression from those who remained well. Ideally as described above, mRNA is obtained from cells of the target organ, but may also include mRNA obtained from blood cells in which  
35 transcription can be altered, e.g., white blood cells. By comparing hybridization patterns for the affected patients vs. the well patients, a defined genetic fingerprint or genes that are differentially expressed to a significant degree may be obtained.



An embodiment of the invention is any gene sequence identified by the methods described therein. These gene sequences associated with the toxic reaction are used to obtain full-length cDNA clones by conventional methods. The genes may be studied in greater detail; e.g. through sequencing and mutation analysis.

5        These gene sequences may be employed in conventional methods to produce isolated proteins encoded thereby. To produce a protein of this invention, the DNA sequences of a desired gene invention or portions thereof identified by use of the methods of this invention are inserted into a suitable expression system. In a preferred embodiment, a recombinant molecule or vector is constructed in which the  
10       polynucleotide sequence encoding the protein is operably linked to a heterologous expression control sequence permitting expression of the human protein. Numerous types of appropriate expression vectors and host cell systems are known in the art for mammalian (including human), insect, yeast, fungal and bacterial expression.

15       The transfection of these vectors into appropriate host cells, whether mammalian, bacterial, fungal or insect, or into appropriate viruses, results in expression of the selected proteins. Suitable host cells, cell lines for transfection and viruses, as well as methods for construction and transfection of such host cells and viruses are well-known. Suitable methods for transfection, culture, amplification, screening and product production and purification are also known in the art.

20       In one embodiment, the essential genes and proteins encoded thereby which have been identified by this invention can be employed as diagnostic compositions useful in the diagnosis of a disease or infection by conventional diagnostic assays. For example, a diagnostic reagent can be developed which detectably targets a gene  
25       sequence or protein of this invention in a biological sample of an animal. Such a reagent may be a complementary nucleotide sequence, an antibody (monoclonal, recombinant or polyclonal), or a chemically derived agonist or antagonist. Alternatively, the essential genes of this invention and proteins encoded thereby, fragments of the same, or complementary sequences thereto, may themselves be used as diagnostic reagents. These reagents may optionally be detectably labeled,  
30       for example, with a radioisotope or colorimetric enzyme. Selection of an appropriate diagnostic assay format and detection system is within the skill of the art and may readily be chosen without requiring additional explanation by resort to the wealth of art in the diagnostic area.

35       Additionally, genes and proteins identified according to this invention may be used therapeutically. For example, genes identified as essential in accordance with this method and proteins encoded thereby may serve as targets for the screening and development of natural or synthetic chemical compounds which have utility as

therapeutic drugs for the treatment of disease states associated with exposure to environmental stimuli. As an example, a compound capable of binding to a protein encoded by an essential gene thus preventing its biological activity may be useful as a drug component preventing diseases or disorders resulting from exposure of the mammalian cells to the environmental stimuli. Alternatively, compounds which inhibit expression of an essential gene are also believed to be useful therapeutically. In addition, compounds which enhance the expression of genes essential to the growth of an organism may also be used to promote the growth of a particular organism.

Conventional assays and techniques may be used for screening and development of such drugs. For example, a method for identifying compounds which specifically bind to or inhibit proteins encoded by these gene sequences can include simply the steps of contacting a selected protein or gene product with a test compound to permit binding of the test compound to the protein; and determining the amount of test compound, if any, which is bound to the protein. Such a method may involve the incubation of the test compound and the protein immobilized on a solid support. Still other conventional methods of drug screening can involve employing a suitable computer program to determine compounds having similar or complementary structure to that of the gene product or portions thereof and screening those compounds for competitive binding to the protein. Identical compounds may be incorporated into an appropriate therapeutic formulation, alone or in combination with other active ingredients. Methods of formulating therapeutic compositions, as well as suitable pharmaceutical carriers, and the like are well known to those of skill in the art.

Accordingly, through use of such methods, the present invention is believed to provide compounds capable of interacting with these genes, or encoded proteins or fragments thereof, and either enhancing or decreasing the biological activity, as desired. Thus, these compounds are also encompassed by this invention.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

The invention is illustrated by the following examples.

## Examples

### Gene expression measurements using Microarrays

#### Source of cloned sequences

- 5 Sequences were derived from several sources. IMAGE clones (human derived cDNA sequences inserted into bacterial plasmids) were ordered from Research Genetics in duplicate. The stocks were streaked out onto agar plates, and 3 colonies per clone were PCR screened with gene specific primers to determine which clones contained the correct sequences. Positive clones were then sequenced (ABI  
10 automated sequencer) and checked against the sequence database to ensure the clones were correct. Six clones were prepared *de novo* by PCR from SB human cDNA. Rat, mouse and dog clones were prepared *de novo* by Reverse Transcriptase-PCR (RT-PCR) from species specific RNAs using gene specific primers and were also sequence confirmed. Stocks containing the correct clones  
15 were preserved as glycerol stocks. In total the microarray comprises of: 77 sequences representing 45 different mammalian genes; and 5 yeast gene sequences.

#### Preparation of DNA for the microarray

- DNA was amplified in 96 well plates on a Perkin Elmer 9600 Thermal Cycler using a mixture of vector primers specific for BSK and pT7T3 (Pharmacia). Total reaction  
20 volume was 100ul containing the following: 1ul of culture from the stock containing the correct clone, 10ul 10X PCR buffer (10X=300mM Tricine, 20mM Magnesium Chloride, 50mM BetaMercaptoEthanol), 0.5ul Perkin Elmer Taq polymerase (5U/ul), 200uM dNTP's (Amersham), 50ng each primer, including Universal Forward and Reverse, as well as 2 primers made to the Pharmacia pT7T3 vector.  
25 38 amplification cycles were carried out: 2 minutes @ 94°C initial soak (1 cycle); 35 seconds @ 94°C (autoincrement 1 sec per cycle); 30 seconds @ 55°C; 1 minute 45 seconds @ 72°C (autoincrement 1 sec per cycle) and a 10 minutes @ 72°C final extension period.

- PCR yields and specificity were checked by agarose gels, and the products were  
30 Ethanol precipitated as follows, in Nunc 96 well V-bottom plates. 10ul of 3M Sodium Acetate was added to the 100ul PCR reaction, mixed, then 275ul of 100% Ethanol was added, and mixed again. Plates were stored at -20°C for 20 minutes, followed by a 30 minute spin in a Beckman GS-6R tabletop centrifuge using

Beckman Microplus carriers, at 3000rpm, 4°C. Pellets were visible at the bottom of the wells, which were washed with 50ul 70% Ethanol, and spun again at 3000rpm for 20 minutes. Pellets were air dried, and resuspended at 300ng/ul in distilled water.

5 Preparation of the Microarray

A 10 ul aliquot from each of the suspended PCR products was mixed with an equal volume of 11M NaSCN (J. T. Baker) and deposited into individual wells of 96-well microtiter plates (Nunc). Approximately 1 nl of each sample was arrayed in duplicate onto silanized (3-aminopropyl trimethoxy silane treated) glass slides using high-speed robotics (Molecular Dynamics Generation II Microarray System). The average diameter of each array element was measured at 215 microns with the spot-to-spot centers at a distance of 500 microns. After printing, the slides were allowed to air dry and then placed into a vacuum oven for 2 hours at 80°C. Prior to hybridization, the slides were washed for 10 minutes in isopropanol, boiled for 5 minutes in ddH<sub>2</sub>O, and air dried.

Preparation of cDNA probes

Probes were prepared by simultaneous reverse transcription and labelling in the presence of a fluorophore. The reactions were carried out with a GibcoBRL Superscript II™ kit (Preamplification System for First Strand cDNA Synthesis) and the protocol was as follows:

10ug of Quiagen™ cleaned sample RNA was mixed with 2ug of anchored oligo dT<sub>20</sub> (Cambio) in DEPC treated water to a final volume of 11.2ul. The mix was heated to 68°C for 10 minutes and returned to ice for 1 minute.

A PCR reaction mix was prepared and kept on ice until required: 2ul X10 PCR buffer (supplied with kit), 2ul 25mM MgCl<sub>2</sub>, 1ul dNTP mix (to give 500uM final concentration of each of dATP, dGTP and dTTP, and a final concentration of 280uM of dCTP), 0.8ul Cy3™ dCTP (Amersham) to give a final concentration of 40uM and 2ul 0.1M DTT to give a total volume of 7.8ul.

The annealed RNA (11.2ul) was added, on ice, to the 7.8ul PCR reaction mix, mixed gently and then incubated at 39.5°C for 5 minutes. 1ul of Superscript II™ (200U/ul) was added, mixed gently, and the mix incubated at 39.5°C for a further 60 minutes. A further 1ul of Superscript II™ was added and incubated at 39.5°C for another 60

minutes. The reaction was terminated by heat inactivating the Superscript II at 68°C for 5 minutes.

RnaseH (2U/ul) was added and incubated at 39.5°C for 20 minutes and the probe cleaned up by running through a Quiaquick™ PCR column according to the  
5 manufacturers instructions.

Yeast control RNA's were made by *in vitro* transcription of cloned YGL097, YDR432, YML113, YFL021 and YGR014 cDNA's using a Riboprobe *in vitro* Transcription System (Promega). For quality assurance purposes, the yeast RNA's were added to the reaction at ratio's of 1:100, 1:1,000, 1:5,000, 1:10,000 and  
10 1:20,000 (wt/wt) respectively. After incubating the reaction at 39.5°C for 60 minutes, an additional 1ul of Superscript II RT was added and incubated at 39.5°C for a further 120 minutes. Following termination of the reaction, 1ul of RNase A (10ug/ul) and 1ul of RNase H were added and incubated at 39.5°C for 20 minutes. Unincorporated label was removed by passing the reaction down a Quiaquick PCR  
15 Purification Kit (Qiagen) according to the manufacturers protocol. To ensure the probe was completely free of unincorporated nucleotide, the above procedure was repeated before drying the probe to completion *in vacuo*.

### Hybridisation

The probe was dried down and resuspended in 12ul (for full-length cover slips) or  
20 4ul (for small cover slips) of hybridisation buffer (5xSSC, 0.1% SDS, 0.25uM pA<sub>20</sub>) and incubated at 100°C for 5 minutes. The probe mixture was pipetted onto the microarray surface and covered with a glass cover slip and sealed with latex glue. The microarray was transferred to a hybridisation oven and incubated at 42°C for 15 hours.

### 25 Washing

The glue and coverslip was removed whilst the microarray slide was immersed in a bath of low stringency buffer (2xSSC, 0.1% SDS) at room temperature and the slide incubated for 5 minutes. The slide was then washed in a high stringency wash (0.5xSSC, 0.1% SDS) on a flat bed shaker at room temperature for 5 minutes. After  
30 repeating the high stringency wash, the microarray slide was quickly placed in a 50ml Falcon tube and centrifuged (2 minutes at 200 x g) to remove any traces of wash buffer.

### Data Capture

Fluorescence from the microarray was detected and quantitated using a Molecular Dynamics Gen II scanner. The fluorescent signal is measured as intensity per mm<sup>2</sup>. A background measurement for each spot was taken in an area surrounding each spot.

5 Analysis of Data

Gene Expression analysis from microarrays

After background subtraction the density for each spot was "normalised" by calculating the ratio of the spot density to the sum of all the spot densities and expressed as the nDxA (for normalised density per unit area). The ratio (T/C) of the treated vs control values was calculated for each spot for each treatment and time point. This was done for spot set 1 and spot set 2 separately. Starting with spot set 1 sequences having T/C ratios of >2 and <0.5 were identified as showing differential gene expression. If the signal was weak (< 0.35) in both spot sets for both treated and control samples, that sample was removed from the analysis as being outside the detectable range. The spot images of each of the identified sequences were examined for dust spots or other "noise" which would give an incorrect densitometric value. Each differentially expressed sequence was ranked according to fold increase/decrease.

## CLAIMS:

1. A method of assessing the genetic effect of a selected environmental factor on a mammalian subject, said method comprising the steps of:
  - (a) providing a plurality of identical grids, each grid comprising a surface on which is immobilized at predefined regions on said surface a plurality of unique defined gene sequence fragments, said oligonucleotide sequences comprising genes or fragments of genes obtained from a healthy member of said mammalian species;
  - (b) exposing mammalian cells, tissue or organ to an environmental factor for a sufficient time to affect transcription of messenger RNA in said cells;
  - (c) extracting and isolating mRNA from said exposed cells, tissue or organ of step (b);
  - (d) extracting and isolating control mRNA from mammalian cells, tissue or organ not exposed to said factor;
  - (e) labelling the mRNA from steps (c) and (d);
  - (f) hybridizing the labeled mRNA from the exposed cells, tissue or organ to a first identical grid to produce a first hybridization pattern detectable by an increased quantity of fluorescence in contrast to the remainder of the grid;
  - (g) hybridizing the labeled control mRNA to a second identical grid to produce a second, control hybridization pattern; and
  - (h) comparing the first and second hybridization patterns to identify any change in said first pattern from the control pattern, indicative of an effect on transcriptional regulation of said mammalian cells, tissue or organ exposed to said factor.
2. The method according to claim 1 wherein said grid comprises unique nucleic acid sequence tags from human genes.
3. The method according to claim 1 or 2 wherein said grid comprises unique nucleic acid sequence tags from genes cloned from a selected tissue or cell line.
4. The method according to any one of the preceding claims wherein said grid comprises unique nucleic acid sequence tags from genes which are particularly relevant to the identification of a selected toxicity.
5. The method according to any one of the preceding claims wherein said mammalian cells are exposed *in vivo* or in culture.

6. The method according to any one of the preceding claims wherein said environmental factor is a change in the diet of said mammal or a physical condition to which the mammal is exposed.
7. The method according to any one of claims 1 to 5 wherein said exposing step comprises:
  - a) administering a transgene into said mammal;
  - b) eliminating a gene from said mammal;
  - c) administering an exogenous compound to said mammal;
  - d) administering an endogenous compound or an analogue thereof to said mammal; or
  - e) exposing said mammal or cell to a pathogenic microorganism.
8. The method according to any one of the preceding claims wherein said transcriptional effect is an increase or decrease in mRNA transcription in the exposed mammalian cells, tissue or organ.
9. The method according to any one of the preceding claims wherein said mammal is selected from a non-human primate, a rodent, a canine, and a human.
10. The method according to any one of the preceding claims wherein said detectable label is a fluorescent molecule.
11. The method according to any one of the preceding claims wherein said defined gene sequences are known genes or fragments thereof.
12. The method according to any one of the preceding claims wherein said defined gene sequences are unknown genes or fragments thereof.
13. A method of predicting the toxic effect of a selected test compound on a mammalian subject, said method comprising the steps of:
  - (a) performing the method of claim 1 by calibrating the grids with a plurality of known and structurally distinct toxicants having a common known toxic effect on mammalian subjects and generating a common "fingerprint" hybridization pattern characteristic of said common toxic effect;



(b) screening a test compound according to the method of claim 1, steps (a)-(f), to generate a test compound hybridization pattern; and

(c) comparing the test hybridization compound to said fingerprint hybridization pattern,

wherein substantial identity between the fingerprint and test patterns indicates that said test compound shares said common toxic effect.

14. The method according to claim 13 further comprising eliminating the test compound from an early stage of drug development on the basis of its hybridization pattern which is substantially identical to the fingerprint.

15. An isolated gene sequence which reacts by altered transcription to exposure to an environmental factor, and which is identified by the method of claim 1.

16. An isolated protein produced by expression of a gene sequence of claim 15.

17. A therapeutic compound capable of modulating expression of the gene sequence of claim 15 for use in the prevention of a toxic reaction to said environmental factor.

18. A therapeutic compound capable of modulating activity of a protein of claim 16 for use in the prevention of a toxic reaction to said environmental factor or the treatment of the toxic reaction.

19. A diagnostic composition useful for the diagnosis of a toxic reaction to an environmental factor comprising a reagent capable of detectably targeting a gene sequence of claim 15.

# INTERNATIONAL SEARCH REPORT

International Application No

PC 98/03445

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12Q1/68 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 13877 A (LYNX THERAPEUTICS INC ; MARTIN DAVID W (US)) 17 April 1997 see whole doc. esp. claims and exp. 3. ---	1-19
A	WO 97 22720 A (BEATTIE KENNETH LOREN) 26 June 1997 see whole doc. esp. claims ---	1-19
X	WO 94 17208 A (XENOMETRIX INC ; FARR SPENCER B (US); MARQUE TODD D (US)) 4 August 1994 see whole doc. esp. claims --- -/--	17, 18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### " Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 February 1999

Date of mailing of the international search report

15/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

# INTERNATIONAL SEARCH REPORT

National Application No.

PCT/GB 98/03445

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHEHA M ET AL: "PARALLEL HUMAN GENOME ANALYSIS: MICROARRAY-BASED EXPRESSION MONITORING OF 1000 GENES"            PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,            vol. 93, no. 20, October 1996, pages 10614-10619, XP002912238            see whole doc esp. discussion            ----</p>	1-19
A	<p>CHEE M ET AL: "ACCESSING GENETIC INFORMATION WITH HIGH-DENSITY DNA ARRAYS"            SCIENCE,            vol. 274, no. 5287, 5 October 1996, pages 610-614, XP002912239            cited in the application            see the whole document            -----</p>	1-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

I. International Application No

PCT/GB 98/03445

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9713877 A	17-04-1997	AU 4277896 A	06-05-1996
		AU 6102096 A	30-12-1996
		AU 7717596 A	30-04-1997
		CN 1193357 A	16-09-1998
		CZ 9700866 A	17-09-1997
		CZ 9703926 A	17-06-1998
		EP 0793718 A	10-09-1997
		EP 0832287 A	01-04-1998
		FI 971473 A	04-06-1997
		JP 10507357 T	21-07-1998
		NO 971644 A	02-06-1997
		NO 975744 A	05-02-1998
		PL 324000 A	27-04-1998
		WO 9641011 A	19-12-1996
WO 9722720 A	26-06-1997	AU 1687597 A	14-07-1997
WO 9417208 A	04-08-1994	AT 160178 T	15-11-1997
		AU 692434 B	11-06-1998
		AU 6124394 A	15-08-1994
		DE 69406772 D	18-12-1997
		DE 69406772 T	12-03-1998
		EP 0680517 A	08-11-1995
		ES 2111289 T	01-03-1998
		GR 3026129 T	29-05-1998
		JP 9503121 T	31-03-1997
		US 5811231 A	22-09-1998